BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35146577)

  • 21. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
    Lee EW; Alanis L; Cho SK; Saab S
    Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the Adverse Event Profile of TheraSphere
    Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of Yttrium-90 Radioembolization for Unresectable Combined Biphenotypic Hepatocellular-Cholangiocarcinoma.
    Malone CD; Gibby W; Tsai R; Kim SK; Lancia S; Akinwande O; Ramaswamy RS
    J Vasc Interv Radiol; 2020 May; 31(5):701-709. PubMed ID: 32127318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calculation of tumour and normal tissue biological effective dose in
    Gallio E; Richetta E; Finessi M; Stasi M; Pellerito RE; Bisi G; Ropolo R
    Phys Med; 2016 Dec; 32(12):1738-1744. PubMed ID: 27876284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.
    Boas FE; Bodei L; Sofocleous CT
    J Nucl Med; 2017 Sep; 58(Suppl 2):104S-111S. PubMed ID: 28864605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.
    Chiesa C; Maccauro M; Romito R; Spreafico C; Pellizzari S; Negri A; Sposito C; Morosi C; Civelli E; Lanocita R; Camerini T; Bampo C; Bhoori S; Seregni E; Marchianò A; Mazzaferro V; Bombardieri E
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):168-97. PubMed ID: 21386789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer.
    Cao X; He N; Sun J; Tan J; Zhang C; Yang J; Lu T; Li J
    Chin Med J (Engl); 1999 May; 112(5):430-2. PubMed ID: 11593513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioembolization, Principles and indications.
    Ahmadzadehfar H; Ilhan H; Lam MGEH; Sraieb M; Stegger L
    Nuklearmedizin; 2022 Jun; 61(3):262-272. PubMed ID: 35354218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with
    Watanabe M; Grafe H; Theysohn J; Schaarschmidt B; Ludwig J; Jochheim L; Jeschke M; Schmidt H; Fendler WP; Moraitis A; Herrmann K; Pomykala KL; Weber M
    J Nucl Med; 2023 Jul; 64(7):1102-1108. PubMed ID: 37290792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
    Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report.
    Kennedy A; Coldwell D; Sangro B; Wasan H; Salem R
    Am J Clin Oncol; 2012 Feb; 35(1):81-90. PubMed ID: 20938320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
    Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
    Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State of the art: radiolabeled microspheres treatment for liver malignancies.
    Deleporte A; Flamen P; Hendlisz A
    Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization.
    Martí-Climent JM; Prieto E; Elosúa C; Rodríguez-Fraile M; Domínguez-Prado I; Vigil C; García-Velloso MJ; Arbizu J; Peñuelas I; Richter JA
    Med Phys; 2014 Sep; 41(9):092503. PubMed ID: 25186412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.